The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (Q34707136)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma |
scientific article |
Statements
1 reference
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (English)
1 reference
James O Armitage
1 reference
Julie M Vose
1 reference
Jane Liesveld
1 reference
Jonathan W Friedberg
1 reference
Jennifer L Kelly
1 reference
Faith Young
1 reference
Steven H Bernstein
1 reference
Derick Peterson
1 reference
Lynn Rich
1 reference
Susan Blumel
1 reference
Nicole K Proia
1 reference
Richard I Fisher
1 reference
Steven Grant
1 reference
John P Leonard
1 reference
14 January 2011
1 reference
1 reference
117
1 reference
10
1 reference
2807-2812
1 reference
Identifiers
1 reference
1 reference
1 reference